Factors Influencing the Conversion of Ocular Myasthenia Gravis to Generalized Myasthenia Gravis: A Retrospective Cohort Study
Wanicha Chuenkongkaew, Niphon Chirapapaisan, Pawimon Chatchutimakorn, Natthapon Rattanathamsakul, Manassawee Joradoln, Pawita Kongthanasomboon, Akarawit Eiamsamarng

TL;DR
This study identifies factors that increase the risk of ocular myasthenia gravis progressing to a more severe, generalized form.
Contribution
The study provides new insights into predictors of conversion from ocular to generalized myasthenia gravis using a large retrospective cohort.
Findings
AChR Ab positivity, thymic abnormalities, and smoking are associated with faster conversion to GMG.
High-dose pyridostigmine use is linked to increased conversion risk, contrary to prior assumptions.
The 2-year conversion rate from OMG to GMG is 25.5%.
Abstract
The conversion rate of ocular myasthenia gravis (OMG) to generalized myasthenia gravis (GMG) lacks definitive predictors. This retrospective cohort study analyzed data collected at Siriraj Hospital between January 2007 and December 2019 to identify factors influencing OMG generalization and the time to conversion. The records of 200 OMG patients were reviewed and both acetylcholine receptor antibody (AChR Ab)‐positive and AChR Ab‐negative patients were included. Seventy‐eight (39%) developed GMG, with a median conversion time of 16 months (IQR 7.88, 33.75) and a 2‐year conversion rate of 25.5%. AChR Ab positivity (adjusted HR 2.88, 95% CI 1.79–4.63), thymic abnormalities (adjusted HR 2.30, 95% CI 1.41–3.74), smoking (adjusted HR 1.78, 95% CI (1.04, 3.03), and pyridostigmine dosages > 180 mg/day (adjusted HR 2.33, 95% CI 1.41–3.87) were significantly associated with shorter conversion…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMyasthenia Gravis and Thymoma · Parkinson's Disease and Spinal Disorders · Ophthalmology and Eye Disorders
